Structure Therapeutics Stock Jumps on Aleniglipron Data
Structure Therapeutics stock rose after midstage readout showed double-digit placebo-adjusted weight loss, prompting re-rating ahead of FDA talks.
KEY TAKEAWAYS
- Phase 2b showed dose-dependent double-digit placebo-adjusted weight loss led by 11.3% at 120 mg.
- Higher-dose cohorts reached placebo-adjusted weight loss up to 15.3%, with no plateau observed at 36 weeks.
- Company flagged titration to improve tolerability and planned a Type B FDA meeting in 1H 2026.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Structure Therapeutics Inc. (NASDAQ: GPCR) shares surged after the company reported on Dec. 8, 2025, that its Phase 2b ACCESS trial showed a placebo-adjusted mean weight loss of 11.3% (27.3 pounds) at 36 weeks for the 120 mg dose of aleniglipron, an oral GLP-1 receptor agonist targeting obesity.
Phase 2b Results and Dose Response
Aleniglipron (GSBR-1290) is Structure Therapeutics’ once-daily oral small-molecule GLP-1 receptor agonist and lead obesity candidate. The ACCESS trial enrolled adults with obesity or overweight with comorbidities, using a placebo-controlled design with percent change in body weight as the primary endpoint.
The dosing regimen started at 2.5 mg and escalated to higher targets, including 120 mg and 240 mg, to improve gastrointestinal tolerability. The company reported dose-dependent weight loss across cohorts, with greater reductions at higher doses. Secondary reports cited placebo-adjusted weight loss up to 15.3% at the 240 mg dose, noting no plateau in weight loss at 36 weeks, suggesting continued decline for that group.
Safety and Development Outlook
Structure Therapeutics described aleniglipron as generally well tolerated. The most common adverse events were gastrointestinal—nausea, vomiting, and diarrhea—consistent with the GLP-1 class. The titration scheme aimed to mitigate these effects. The 120 mg arm had a 10.4% adverse event-related treatment discontinuation rate over 36 weeks.
Investors responded strongly, with shares rising more than 103% following the topline release. At least one analyst maintained a Strong Buy rating, citing the combination of oral convenience and double-digit placebo-adjusted weight loss. Management and analysts have framed aleniglipron as a potential best-in-class oral GLP-1 therapy compared with injectable alternatives.
Structure plans a Type B End-of-Phase-2 meeting with the U.S. Food and Drug Administration in the first half of 2026 to discuss pivotal trial design. Analysts expect a potential Phase 3 start around mid-2026, contingent on FDA feedback and internal planning. Aleniglipron remains investigational with no marketing approvals reported. The outcome of the FDA meeting will guide dose selection and endpoints for any registrational program.
